Sprint Bioscience's stock is surging after the company announced an agreement with Gilead Sciences to sell its preclinical cancer program, TREX1. The deal includes an upfront payment of USD 14 million, with the potential for further milestone payments bringing the total deal value up to USD 400 million. BioStock reached out to CEO Johan Emilsson for more information.
Read the full article at biostock.se:
https://biostock.se/en/2025/11/sprint-bioscience-saljer-cancerprogrammet-trex1-till-gilead/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se